Enquirer Consulting Group

Reachable Buyer Map

Prepared for Craig Quinn · United States · August 2026
This counts the United States only. From the outside, the market for life sciences services reads as two very different buyers wearing the same badge: the large company with a standing roster of approved partners, and the emerging one building a commercial and medical function for the first time. This page sets out where the second kind sits, the titles that sign, and roughly how many of them there are.
Public-market pharma and biotech
The clearest enumerated segment, because a listing forces disclosure. Pipeline stage, cash runway, trial readouts and hiring plans all sit in public filings, which makes this the one group where the timing of a need can be read before anyone asks for help. Most of these companies run lean teams and buy the capability rather than hire it.
Who signs: the chief commercial officer, the head of medical affairs, the VP of marketing, the head of commercial training.
700 to 1,000
US-listed pharmaceutical and biotechnology companies; private and venture-backed companies are not counted here
Registered drug manufacturers
The companies behind these registrations span originators, specialty makers and packagers, and they include a long tail of privately held firms that never appear in a public filing. Slower to identify than a listed company and easier to reach once identified, because the decision usually sits with one or two named people rather than a committee.
Who signs: the president or general manager, the VP of commercial operations, the head of regulatory and medical, the head of learning and development.
3,000 to 6,000
US establishments registered to make or package drug products; sites rather than companies, so one company can appear more than once
Medical device and diagnostics
The adjacent market that buys the same disciplines under different names: clinical education, field team enablement, evidence communication and launch readiness. Larger by company count than the drug side and generally less crowded with incumbent partners, which is what makes it worth a separate line rather than a footnote.
Who signs: the VP of marketing, the head of clinical affairs, the head of professional education, the head of sales training.
10,000 to 15,000
US registered device establishments; the register includes plants and specification developers, so sites again rather than companies
First launches
The smallest group on this page and the most valuable one, because a company launching for the first time has to build every commercial and medical capability at once and has no roster to fall back on. The approval date is public, the run-up is long, and the buying decisions get made twelve to eighteen months before anyone ships a product.
Who signs: the chief executive at smaller companies, the chief commercial officer, the head of medical affairs, the head of market access.
45 to 60
novel drug approvals in the US in a typical year, alongside a larger number of new indications and label expansions
Private and venture-backed companies
Numerically the largest pool of pre-commercial life sciences companies in the country, and the one nobody can hand you as a list. There is no register of private biotech, so this group gets assembled from financing announcements, trial registries and hiring signals, one company at a time. Stated plainly: that difficulty is the reason the segment stays underworked by everyone.
Who signs: the chief executive, the chief medical officer, the head of corporate development, the board member who ran a launch before.
No public register
identified from financing, trial and hiring signals rather than counted; deliberately assembled as a named list

Where the openings are

1
In this market, first contact usually happens through a relationship or a preferred-vendor list. That works well for the companies who already keep a roster, and it is close to useless for the ones building a function for the first time, who have no roster to be on. Those companies are reached by name or not at all.
2
This work is bought at a moment, not on a cycle. A trial readout, a financing round, a filing accepted, a first commercial hire, a new head of medical affairs in post. Every one of those is visible from the outside if someone is watching several hundred named companies for them, and invisible to anyone waiting to be shortlisted. Watching at that scale is mechanical work.
3
The emerging and mid-size band is the underworked one. Big enough to have a real launch problem, small enough that one conversation with a commercial lead settles it, and rarely competed for by partners who arrive through conference stands and procurement portals. It is also the band where the buyer still answers their own email.
4
This is a distribution gap, not a credibility one. Nobody in this category needs help proving they can do the work. The machinery that puts a named list of several hundred commercial and medical leaders in front of a written message, on a schedule, and tracks what comes back is a build, and most firms in this category never make it. That is the part we build, and we hand it over when it works.
Built from public US federal registry and market-listing data, current to the most recent published year. Counts are banded deliberately. Establishment counts are sites rather than companies, so one company can appear more than once. Sector and product codes are self-reported. Privately held companies and the timing of a buying decision are not covered by any public register and are described rather than counted.
It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com